Lesson plan
ONO-2020
ONO-2020 is an epigenetic modulator, immunomodulator, and possible cognitive enhancer which is under development for the treatment of agitation including due to Alzheimer's disease. It is taken orally. The drug's exact mechanism of action or biological target does not yet appear to have been disclosed. ONO-2020 is under development by Ono Pharmaceutical. As of May 2025, it is in phase 2 clinical trials for treatment of agitation and Alzheimer's disease. The chemical structure of ONO-2020 does not yet appear to have been disclosed.
Article summary
ONO-2020 is an epigenetic modulator, immunomodulator, and possible cognitive enhancer which is under development for the treatment of agitation including due to Alzheimer's disease. It is taken orally. The drug's exact mechanism of action or biological target does not yet appear to have been disclosed. ONO-2020 is under development by Ono Pharmaceutical. As of May 2025, it is in phase 2 clinical trials for treatment of agitation and Alzheimer's disease. The chemical structure of ONO-2020 does not yet appear to have been disclosed.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.